NDSN — Nordson Corporation

Summary of Nordson Corporation Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Record Sales: Q1 sales reached $669 million, a 9% increase from $615 million in Q1 2025, with 7% organic growth.
• EBITDA: Increased by 8% year-over-year to $203 million, maintaining a 30% EBITDA margin.
• Adjusted Earnings Per Share: Reached a record $2.37, up 15% from $2.06 in the prior year.
• Free Cash Flow: Generated $123 million, translating to a 105% conversion rate on net income.
• Net Income: Totaled $133 million, or $2.38 per share.
• Debt and Cash Position: Net debt stood at approximately $1.9 billion with a leverage ratio of 2.1x. Cash on hand was $120 million.

2. Strategic Updates and Business Highlights

• Segment Performance:
  • Industrial Precision Solutions (IPS): Sales of $327 million (9% increase), with organic growth of 3%. Growth driven by packaging and automotive stabilization.
  • Medical and Fluid Solutions (MFS): Sales of $193 million (flat year-over-year), with organic growth of 3% impacted by divestiture and weather-related production losses.
  • Advanced Technology Solutions (ATS): Sales of $149 million (23% increase), with 21% organic growth driven by semiconductor applications.
• Shareholder Returns: $82 million in share repurchases and $46 million in dividends paid.
• Investment in Growth: $18 million invested in capital projects to drive future growth.

3. Forward Guidance and Outlook

• Q2 2026 Guidance: Expected sales between $710 million and $740 million, with adjusted earnings per share forecasted at $2.70 to $2.90.
• Full Year 2026 Guidance: Sales projected between $2.860 billion and $2.980 billion, reflecting a 4.5% increase at the midpoint. Adjusted earnings expected in the range of $11 to $11.60 per diluted share, a 10% increase at the midpoint.
• Market Conditions: Continued order momentum and backlog growth of approximately 4% year-over-year.

4. Bad News, Challenges, or Points of Concern

• Medical Segment Slow Start: MFS experienced slower growth than expected, attributed to weather impacts and a divestiture. The segment's growth is projected to be mid-single digits for the year.
• Geographic and Product Mix Impact: Lower margins in IPS due to geographic mix and foreign currency fluctuations, which could affect future profitability.
• Market Volatility: While demand is currently strong, there are concerns about potential broader pullbacks in end market demand in the second half of the year.

5. Notable Q&A Insights

• Margin Dynamics: Management indicated that the current margin challenges are primarily due to geographic and product mix rather than a fundamental change in margin outlook.
• Medical Segment Confidence: Despite a slower start, management expressed confidence in returning to mid-single-digit growth due to strong underlying demand and a healthy project pipeline.
• ATS Growth Drivers: The growth in ATS is driven by semiconductor demand, with expectations for continued strength in dispense applications and a recovering X-ray business.
• M&A Activity: Nordson is actively pursuing acquisitions in medical components and test and inspection technologies, maintaining a disciplined approach to potential deals despite elevated multiples in the market.

Overall, Nordson's Q1 2026 performance reflects strong growth across several segments, particularly in advanced technologies, while navigating challenges in the medical sector and maintaining a cautious outlook for the remainder of the year.